Earendil Labs has raised $787m in financing rounds. The funding will accelerate Earendil Labs’ AI-driven R&D platform, expand its interdisciplinary teams, and advance a growing pipeline of antibody and biologics programmes, with the goal of delivering first-in-class and best-in-class therapies for patients with serious diseases.
“AI is at the core of everything we do — not as a research tool, but as a production engine for real therapeutic programmes,” said Jian Peng, founder and CEO of Earendil Labs.
“This financing allows us to operate at a fundamentally different scale, advancing multiple programmes toward the clinic while building an R&D organization designed for long-term impact.”
Earendil Labs integrates artificial intelligence across the full life cycle of biologics R&D, enabling the systematic generation and progression of differentiated therapeutic programmes. The company’s AI-native platform has produced more than 40 programmes, including HXN-1001, a half-life extended anti-TL1A antibody which is ready for phase 2 clinical development, together with multiple IND submissions planned in 2026 and 2027.
“Our focus is ultimately on patients suffering from diseases that still lack effective treatment options,” said Zhenping Zhu, co-founder, president and co-CEO of Earendil Labs.
“This funding greatly strengthens our ability to translate AI-enabled innovation into potentially transformative medicines and provides opportunities to partner with global leaders to accelerate our research and development programmes worldwide. “
The platform’s productivity and R&D execution are further validated through strategic collaborations with Sanofi. In 2025, Earendil Labs announced a worldwide exclusive license agreement with Sanofi for next-generation bispecific antibodies for autoimmune and inflammatory bowel diseases, covering HXN-1002 and HXN-1003. More recently, Earendil Labs and Sanofi entered a broader strategic collaboration to apply its AI-driven discovery platform to multiple autoimmune and inflammatory disease programmes.
With the funding, Earendil Labs plans to scale its AI-driven research and development across biologics discovery and development while expanding its scientific, engineering, and translational teams to support pipeline growth. The capital will also advance multiple internal programmes toward clinical milestones and deepen strategic partnerships to accelerate the delivery of innovative biologics to patients globally.